A股異動 | 誠志股份大漲近8% D-核糖生產線正在積極復工
格隆匯2月25日丨誠志股份(000990.SZ)大漲近8%,報15.75元,總市值197億元。誠志股份週一在互動平台上表示,D-核糖是多種核苷類、抗腫瘤等多種藥物的重要中間體和起始原料,目前臨牀使用的抗病毒藥物中近50%是核苷類藥物,比如卡培他濱、替卡格雷等抗病毒藥物,均使用D-核糖作中間體原料。作為全球最大的D-核糖生產企業,公司多年來一直為國內外相關核苷類藥物研製企業供應D-核糖原料,目前公司D-核糖生產線正在克服疫情積極復工,優先保障相關供應。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.